Monopar Therapeutics — Director's Dealing 2020

Feb 21, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2020-01-31

Reporting Person: Mazar Andrew Paul (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-31	Restricted Stock Units	$0	A	7748	Acquired		Common Stock (7748)	Direct
2020-01-31	Stock Options	$14.35	A	32193	Acquired	2030-01-31	Common Stock (32193)	Direct

Footnotes

F1: Restricted stock units vest 25% on January 1, 2021, 25% on January 1, 2022, 25% on January 1, 2023, and 25% on January 1, 2024.

F2: Stock options vest 6/48ths on the 6-month anniversary of vesting commencement date of January 1, 2020, and 1/48th per month thereafter